DARE — Dare Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00
- $28.16m
- $17.69m
- $2.81m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.3 | -27.4 | -38.7 | -30.9 | -30.2 |
Depreciation | |||||
Non-Cash Items | 0.26 | 0.58 | 1.18 | 2.14 | 2.61 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.677 | 1.54 | 8.73 | 10.7 | -11.3 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -13.3 | -25.2 | -28.8 | -18.1 | -38.9 |
Capital Expenditures | 0 | -0.018 | -0.015 | -0.063 | -0.629 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 6.14 | 0 | — | — | — |
Acquisition of Business | |||||
Sale of Business | |||||
Cash from Investing Activities | 6.14 | -0.018 | -0.015 | -0.063 | -0.629 |
Financing Cash Flow Items | — | — | — | — | 4.72 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 5.15 | 25.1 | 75.8 | 1.34 | 15.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.03 | -0.111 | 47 | -17 | -23.9 |